MedTech
-
The Moment Optionality Begins to Narrow in MedTech Scale-Ups
If you have not yet watched this week’s Signal Before Scale episode on Olive AI and invisible momentum collapse in MedTech, I would strongly encourage you to begin there. The video explores a strange phenomenon increasingly visible across healthcare technology: How organisations can appear externally successful while internally becoming progressively heavier, slower, and more fragile.…
-
The Hidden Variable Inside MedTech Scale-Ups Right Now
In the previous article, I wrote about the moment optionality begins to narrow in MedTech scale-ups. The natural question for boards is what determines whether that shift is recognised early, or only noticed once timelines begin to stretch. Across portfolios, the answer is rarely capital, rarely technology, and it is almost never effort. The hidden…
-
The Moment Optionality Begins to Narrow in MedTech Scale-Ups
A MedTech company can feel as though it is moving closer to market, while at the same time moving closer to only one version of its market. That difference is easy to miss. Early in a scale-up journey, optionality feels almost unlimited. Multiple regulatory paths look possible. Several clinical strategies appear sensible. Different positioning stories…
-
When Regulatory Conversations Quietly Rewrite the Strategy
Most MedTech strategies are not rewritten in board meetings. They are rewritten gradually, often almost invisibly, through conversations with regulators that at the time appear to be clarifications rather than decisions. This is not because regulators intend to shape company direction. It happens because evidence-based environments reveal reality step-by-step, and each clarification alters what the…
-
Why Boards Often Realise the Value of a CMO Too Late
Clinical leadership in MedTech is rarely treated as a strategic variable at the start. In early stages, it often appears procedural. A role associated with compliance, trials, and regulatory navigation. Certainly treated as important but not always central to valuation. That perception tends to change when the inevitable pressure mounts. As scale approaches, clinical judgement…
-
MHRA Proposes Indefinite Recognition of CE Marked Medical Devices in Great Britain
You did not build your company to spend its best energy navigating paperwork. You built it to move something that matters, a device, an idea, a breakthrough, from concept to clinic and from prototype to patient. The ambition has always been clear: to get life-saving products into the hands of clinicians efficiently, without unnecessary friction…
-
The Leadership Gap MedTech Will Feel Before It Can Measure
In the coming years, many MedTech organisations will experience delays, friction, and regulatory setbacks that do not feel like failures. They will feel like bad luck. A certification that takes longer than expected. A product that stalls late in development. A launch window that quietly slips. In most cases, the root cause will not be…
ai, artificial-intelligence, business, CTO, How boards assess technical leadership, How MedTech leadership decisions affect regulation, leadership, Leadership risk in regulated healthcare, Leadership Strategy, management, MedTech, MedTech board advisory, MedTech CMO recruitment, MedTech CTO recruitment, MedTech executive hiring, MedTech leadership, MedTech leadership risk, Regulated MedTech leadership, Senior technical leadership MedTech, Tech Leadership, technology, Why MedTech hiring fails at senior level, Why MedTech launches get delayed
-
Why Most MedTech Leadership Pipelines Miss Their Best Candidates
Most medtech leadership pipelines are working exactly as intended, and that is why they so often miss the leaders who matter most. They are not broken, under-resourced, or poorly run. In many cases, they are carefully designed systems built to reduce risk, move efficiently, and surface candidates who feel safe to appoint. That intention makes…
Harun Rabbani 